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ABSTRACT 
Immunoslot blot assays have been used for the analysis of many DNA adducts but problems 
are frequently encountered in achieving reproducible results. Each step of the assay has been 
systematically examined and it was found that the major problems are in the DNA 
fragmentation step and the use of the manifold apparatus. Optimisation was performed upon 
both the malondialdehyde-deoxyguanosine adduct (M1dG) and the O
6
-carboxymethyl-
deoxyguanosine adduct (O
6
CMdG) to demonstrate the applicability to other DNA adducts. 
Blood samples from the EPIC study (n = 162) were analysed for M1dG adducts and the data 
showed no correlation with adduct levels in other tissues indicating that the EPIC blood 
samples were not useful for studying M1dG adducts. Blood samples from a processed meat vs 
vegetarian diet intervention (n = 6) were analysed for O
6
CMdG and many were below the 
limit of detection. The reduction of background adduct levels in standard DNA was 
investigated using chemical and whole-genome amplification approaches. The latter gave a 
sensitivity improvement of 2.6 adducts per 10
7
 nucleotides for the analysis of O
6
CMdG. 
Subsequent reanalysis for O
6
CMdG showed a weakly significant increase in O
6
CMdG on the 
processed meat diet compared with the vegetarian diet, demonstrating that further studies are 
warranted. 
 
Keywords: immunoslot blot assay; DNA adducts; O
6
CMdG; M1dG; genome amplification; 
EPIC; processed meat 
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INTRODUCTION 
Exposure of cellular DNA to exogenous and endogenous genotoxic agents results in a variety 
of DNA modifications, e.g. DNA adducts, which could be potentially mutagenic and 
represent an initiation step for carcinogenesis. The identification and quantification of very 
low concentrations of DNA lesions in vivo in multi-cell samples requires ultra-sensitive 
methodologies. This is true particularly for the analysis of human samples, where small 
amounts of sample and therefore DNA is normally available. The immunoslot blot (ISB) 
assay was first developed by Nehls and coworkers in 1984 (1). Since then the assay has been 
applied to the detection of several DNA adducts formed both in vitro (2-5) and in vivo (6-12) 
and the use of both monoclonal  (13, 14) and polyclonal (2) antibodies has been described. 
Whilst the former are more specific, the latter tend to have greater sensitivity. In a previous 
paper the development of a very sensitive ISB assay was described for the detection of the 
endogenous adduct malondialdehyde-deoxyguanosine (M1dG, Fig. 1), derived from lipid 
peroxidation, in small amounts of human white blood cell and gastric biopsy DNA and the 
potential for its use in human biomonitoring studies (15) using a monoclonal antibody (16).  
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Fig. 1 Structures of the DNA adducts, M1dG and O
6
CMdG 
The ISB has since been used to detect the M1dG adducts in mice livers (17) and human 
colorectal mucosa (18) and more recently we applied this methodology to the measurement 
of O
6
-carboxymethyl-deoxyguanosine adducts (O
6
CMdG, Fig. 1), using a polyclonal 
antibody (19), derived from nitrosated amines, for in vitro studies and in human blood 
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samples of volunteers consuming a high red meat diet (20). The latter was confirmed by 
alternative qualitative methods of measuring O
6
CMdG (21). 
The advantage of the ISB assay over many other methods of measuring DNA damage is that 
it only requires small amounts of DNA (1 g per sample) and replicates can be analysed on 
the same blot. The handling of radioactive compounds for methods such as 
32
P-postlabelling 
is eliminated and a higher throughput of samples can be achieved, up to 18 samples in two 
days. However, the assay has many steps and problems can occur at any point; during 
fragmentation and denaturation of the double-stranded (DS) DNA standards and samples, 
immobilisation of the resulting single-stranded (SS) DNA on a nitrocellulose membrane, 
incubation with the primary antibody  followed by incubation with a secondary antibody 
tagged with an enzyme complex such as horseradish peroxidase, treatment with a 
chemiluminescence reagent and finally in the acquirement of the chemiluminescence image. 
These problems have deterred researchers and the literature reveals relatively few studies that 
have used the ISB methodology. This study sought to identify, and provide solutions to, the 
most important factors in achieving reliable data from the ISB. Furthermore, a prerequisite 
for the ISB assay is the availability of an appropriate standard, for example calf thymus (CT) 
DNA containing known amounts of modification, in order to generate calibration lines on the 
blot. However, a common problem of measuring endogenous DNA adducts is the presence of 
background levels of the lesion of interest in untreated CT-DNA. This means that the 
detection limit of the assay is potentially lower than the actual limit set by the standard DNA. 
The sensitivity of the assay was sought to be improved either by elimination of the adduct in 
standard CT-DNA or by masking it such that it is not recognised by the primary antibody. 
The use of chemical modification and whole genome amplification approaches are described.  
In addition, an interlab comparison was carried out and the analysis of blood samples was 
investigated as it was found that adducts levels in blood can be very low and thus difficult to 
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measure. The analysis of blood samples is particularly relevant for biomonitoring studies if 
they are to be as non-invasive as possible. The results for M1dG in colorectal mucosa samples 
from the EPIC study had been previously reported and a weak correlation was found with 
dietary saturated fat (18) which was corroborated in an intervention study using blood 
samples (22). The corresponding EPIC blood samples have now been analysed and the results 
are reported in this paper. The analysis of O
6
CMdG in blood was also investigated in 
volunteers that had consumed high levels of processed (nitrite-preserved red) meat compared 
to a vegetarian diet in a small scale pilot study. Previous research had identified the presence 
of the O
6
CMdG adduct in volunteers consuming a high red meat diet (20) and established 
that processed meat leads to higher levels of DNA damage than red meat (23). Thus, the 
present study sought to identify differences in O
6
CMdG adducts between a diet high in 
processed meat compared to a vegetarian diet. 
MATERIALS & METHODS 
Tetramethoxypropane (TMP), guanine, 2’-deoxyadenosine, 2’-deoxyadenosine-3’-
monophosphate, CT–DNA (D1501), genomic ultrapure CT-DNA (D4764), propidium iodide 
(PI), micrococcal nuclease (MN), nuclease P1 (NP1) and goat anti-rabbit IgG horseradish 
peroxidase conjugate were obtained from Sigma-Aldrich (Dorset, UK). Calf spleen 
phosphodiesterase (CSPDE) and human genomic DNA (#1691112) were purchased from 
Boehringer Mannheim (Lewes, East Sussex, UK). Goat anti-mouse IgG horseradish 
peroxidase conjugate was purchased from Dako (Denmark). Phosphate buffered saline (PBS) 
tablets were purchased from Oxoid Ltd. (Basingstoke, UK). Qiagen genomic-tips 100/G were 
purchased from Qiagen Ltd (Crawley, UK). GenomiPhi™ V2 DNA Amplification Kits were 
purchased from GE Healthcare (Little Chalfont, UK).  Methanol used for HPLC analysis was 
for fluorescence application and purchased from Fisher. All other reagents and solvents of 
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analytical grade or HPLC grade were obtained from Fisher Scientific Ltd. (Loughborough, 
UK) or Sigma-Aldrich. 
Synthesis of analytical standards 
M1G (17), M1dG (15), and O
6
CMdG (19) were prepared as previously described. O
6
CMG 
was obtained via acid hydrolysis of O
6
CMdG in 0.1 M formic acid at 70º C for 1 h.  
Preparation of M1dG-DNA standards 
Two highly modified M1dG-DNA standards were prepared independently in different 
laboratories as previously described by treating CT-DNA with malondialdehyde (MDA) (15). 
The DNA concentration and purity were determined by UV spectroscopy using the 
absorbance at 260 nm and the A260/A280 ratio on either a GeneQuant II RNA/DNA calculator 
(Pharmacia Biotech) or a Uvikon XL (Biotek) with LabPowerJ DNARNA purity check 
software. DNA was digested by either acid hydrolysis (see below) or enzymatic digestion 
(15) to the free purines or deoxynucleotides and deoxynucleosides respectively and the DNA 
concentration and adduct levels quantified by HPLC on a Waters Alliance system equipped 
with a Waters 996 photodiode array detector and a Waters 474 scanning fluorescent detector 
or a Waters 600E or Waters 2690 system equipped with a Waters 484 UV and a Waters 470 
fluorescence detector with a narrow-bore Hypersil BDS C18 column (3 µm, 100 x 2.1 mm) 
including a prefilter. The digested DNA was analysed in triplicate (10 µl/sample) using an 
isocratic flow rate of 0.2 ml/min with 0.1 M triethylammonium acetate (pH 5.0), 1% 
methanol for M1G or 4% methanol for M1dG with fluorescence detection (Ex 360 nm, Em 
500 nm). Normal bases were analysed at 260 nm by UV. The modified DNA was diluted to a 
DNA concentration of 100 g/ml and an M1dG concentration of 10 fmol/µg DNA with 
unmodified CT-DNA. Further dilutions were made with 100 g/ml unmodified CT-DNA to 
produce standards in the range of 0-10 fmol M1dG/μg DNA for the ISB calibration line.  
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Preparation of O
6
CMdG-DNA standards 
Highly modified O
6
CMdG-DNA standards were prepared as described previously (20)
 
by 
treating CT-DNA with
 
potassium diazoacetate (KDA). O
6
CMdG-DNA was analysed by 
HPLC as described above using a water/methanol gradient (70:5 to 40:35 in 15 mins) and 
25% 0.1 M heptafluorobutyric acid, with UV analysis for normal bases (260 nm) and 
fluorescence detection of O
6
CMdG and O
6
CMG (Ex 286 nm, Em 378 nm). Quantification 
and preparation of standards for the ISB assay was as described above to give standards in the 
range 0-10 fmol O
6
CMdG/µg DNA and 100 µg/ml DNA.  
Optimisation of adduct-DNA acid hydrolysis 
M1dG-DNA was incubated with 0.1 M and 1 M formic acid or 0.1 M and 1 M HCl at 70° C 
for 1 h, and 0.1 M formic acid or 0.01-6 M HCl at 100° C for 1 h
 
(24) using 2 µg M1dG-DNA 
in 40 µl solution. The solutions were evaporated to dryness and redissolved in 40 µl of 1 mM 
formic acid or 1 mM HCl.  
O
6
CMdG-DNA (20 µg) was incubated with 0.1 M formic acid at 70° C for 1 h (17), 0.1 M 
HCl at 100° C for 30 min, 1 M TFA at RT or 50° C for 1 h (25), and  1 M acetic acid at 50° C 
for 3 h,  and then neutralised with 0.1 M NaOH, and evaporated to dryness and redissolved in 
40 µl 0.1% HFBA. 
Optimisation of the immunoslot blot assay  
The ISB assay was developed from a previous method (15) with modifications to the original 
procedure to improve DNA binding (see below) to the nitrocellulose (NC) membrane (0.1 
m, BA79, or 0.45 m, BA85 Schleicher & Schuell, Dassel, Germany). The primary 
antibody concentrations were: anti-M1dG monoclonal antibody D10A1 (16) diluted 1:90,000, 
and anti-O
6
CMdG polyclonal antibody (19) diluted 1:800. The secondary antibody 
concentrations were: goat anti-mouse IgG horseradish peroxidase conjugate diluted 1:4,000, 
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and goat anti-rabbit IgG horseradish peroxidase conjugate diluted 1:2,000. Enzymatic activity 
was visualised by bathing the membranes for 5 min in Supersignal Ultra (Pierce). 
Chemiluminescence signals from the NC membrane were captured using either the Biorad 
Fluor STM Multimager with the Multianalyst software (Biorad) or on the Kodak Image 
Station 440CF with correction for local background. 
Comparison of sonication methods 
DNA fragmentation was investigated for a number of different sonicators and times: DNA 
samples were 1) sonicated in a Ultrawave U100H and Fisherbrand FB100 bath (2-20 mins 
followed by heat-denaturation at 100º C for 10 min and then kept on ice for 10 min; 2) only 
heat-denatured (no sonication); 3) heat-denatured first and then sonicated; 4) sonications 
were carried out on ice. DNA fragmentation was monitored either by gel electrophoresis or 
by binding to the NC membranes as measured by PI staining.  
Improvement of DNA binding to nitrocellulose membrane 
The following conditions were examined in order to improve DNA binding to NC 
membranes and assessed using the ISB and PI assays: 1) Membranes were baked in a vacuum 
oven at 80° C for 1.5 h (1), 2) NC membranes were bathed for 5 min in SSC buffer (0.75 M 
NaCl, 0.075 M trisodium citrate, pH 7.0) prior to baking, 3) Effects of sample temperature: 
samples were either removed from the icebath after completion of the denaturation step or 
kept at 4 C until application to the membrane, 4) decreasing the vacuum applied during 
sample aspiration and 5) adjustment of the manifold apparatus (Minifold II, 72 well slot blot 
microfiltration apparatus (Schleicher & Schuell)) via insertion of additional spacers. 
Agarose gel electrophoresis 
A volume equivalent to 1 µg DNA or 1 µl of marker were mixed with 2 µl of gel loading 
solution (type 1, 6x concentrate, Sigma G-7654) and made up to 10 µl with ultrapure water. 
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A 2% agarose gel containing ethidium bromide (2.0 µl/100 ml gel) (EtBr, 10 mg/ml) was run 
in 1xTBE buffer (working solution: 90 mM Tris-borate, 2 mM EDTA; pH 8.0) at 120 V for 
1.75 h. A 100 basepair (bp) DNA ladder (Life Technologies, No. 15628-019, 0.25 µg/µl) was 
used as a marker (fragment sizes: 2072, 1500, 1400, 200, 100 bp). The gel image was 
captured using the Biorad Fluor-S
TM
 MultiImager.  
Quantification of DNA binding by propidium iodide staining 
Two CT-DNA calibration lines (0.10-2.50 µg DNA/well) were prepared on the same 
membrane. One half was washed twice for 10 min in 50 ml PBS and the other overnight and 
then both were stained with PI for 3 h. Variations in DNA binding of different sources of 
DNA were examined by comparison of CT-DNA, M1dG-DNA, O
6
CMdG-DNA, Boehringer 
Mannheim (BM) standard DNA and human WBC DNA diluted to give 0.1-2.5 g DNA/well 
and adduct levels (where appropriate) of 0-10 fmol adduct/µg DNA. The ISB procedure was 
followed and the membranes incubated overnight with PI following a 10 min wash. All 
membranes were washed for 1 h in PBS (50 ml) prior to capture of the fluorescent signal 
using either Biorad Fluor-S
TM
 MultiImager or Kodak Imager with filters for >520 nm.  
Reduction of M1dG adduct levels by chemical modification 
Highly modified M1dG-DNA solutions (50 g, 18 pmol M1dG/gDNA) were dissolved in 
KP buffer (10 mM K2HPO4, pH 8, 8.5 and 9) and treated with methoxyamine (5, 20 and 50 
mM). The samples were incubated at -20 C for 16-66 h and then 37 C. Aliquots (4 g) were 
taken at 0-24 h, enzymatically digested to the deoxynucleosides and analysed by HPLC.  
Unmodified CT-DNA (350 g) was dissolved in KP buffer, pH 8 and treated with 0-5 mM 
methoxyamine, incubated for 16-94 h at -20 C followed by 0-24 h incubation at 37 C. DNA 
was precipitated with 0.8 vol isopropanol, washed with 70% ethanol and redissolved in water. 
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CT-DNA samples were analysed by immunnodot blot (IDB) with PI correction and the 
adduct levels calculated from calibration lines acquired with the unmodified CT-DNA. 
Reduction of adduct levels by DNA amplification 
10 ng CT-DNA, M1dG-DNA (21 pmol M1dG/ug DNA) O
6
CMdG-DNA (1.3 pmol 
O
6
CMdG/ug DNA) and the kit control were amplified using a GenomiPhi™ kit following the 
manufacturer's protocol. The DNA was purified by precipitation with a sodium 
acetate/EDTA buffer (final concentration = 0.25 M/0.04 M, pH 8.0) and quantified by UV. 
The adduct levels in the amplified DNA samples were quantified by ISB using the original 
standards. Calibration lines were compared for the amplified and original CT-DNA with 
standards in the range 0-3 fmol/ug DNA. 
Human blood samples for M1dG analysis 
162 blood samples from the EPIC study that had been collected at the same time as colon 
biopsy samples (18) were analysed for M1dG adducts.  
Human blood samples for O
6
CMdG analysis 
Healthy males (n = 4) and females (n = 2) from Cambridgeshire were recruited through local 
advertisements and participated in a randomised crossover intervention study consuming 
processed meat versus vegetarian diets as described previously (23). The participants were 
between 25 and 50 years of age, nonsmokers, free from diabetes and bowel disease, not 
taking medication affecting the gut for at least 3 months prior to the study, not pregnant and 
not participating in another biochemical intervention study at the same time. The studies were 
approved by the Cambridge Local Research Ethics Committee. Blood samples were collected 
at the end of each dietary period and the DNA isolated using Qiagen kits.  
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Analysis of blood samples 
All blood samples were analysed using the optimised ISB assay on a 0.1 µm membrane with 
PI correction. Calibration lines were in the range of 0-5 fmol adducts/µg DNA using either 
CT-DNA or amplified CT-DNA to produce the standards. Analyses were performed in 
triplicate on the same blot and only the results with a SD of < 20% were included in the 
reported data. A human DNA QC sample (Boehringer Mannheim) was included in all assays 
for M1dG and the results rejected if the QC had a SD of > 20% for the triplicate analyses or 
the QC result was > 2 SD from the mean of all the QC results (2.00 adducts per 10
7
 normal 
bases +/- sd 1.27). The limit of detection was 0.2 adducts per 10
7
 normal nucleotides (15). 
Statistics 
Statistical analyses were performed using SPSS for Windows version 15.0. Correlations 
between M1dG adduct levels in blood and colon biopsies were assessed by Spearman rank 
correlation coefficient. Differences in O
6
CMdG adduct levels between dietary periods were 
assessed by Wilcoxon signed rank tests for related samples. 
RESULTS 
Preparation of standards for ISB assays 
Under mild acid hydrolysis conditions only the purine bases are completely released. Acid 
hydrolysis of DNA samples was not found to affect the guanine:adenine ratio under any of 
conditions tested. However, the ratio for M1G:G varied considerably; incubation with 0.1 M 
formic acid at 70° C released the highest level of adduct (M1dG:G 0.13:1) whereas 0.01-6 M 
HCl at 70-100° C resulted in reduced adduct levels, and release of pyrimidine bases in the 
highest acid concentrations. Similarly, 0.1 M HCl gave a reduced level of O
6
CMG adducts 
relative to 0.1 M formic acid. Hydrolysis of O
6
CMdG with 1 M TFA (25) was not as 
effective as 0.1 M formic acid as was evident from the presence of a small peak for O
6
CMdG 
 12 
in the chromatogram of the hydrolysed sample.  Hence, 0.1 M formic acid was determined to 
be the best method for hydrolysis with respect to both DNA concentration and adduct 
quantitation for both M1dG and O
6
CMdG.  
Two M1dG-DNA standards were prepared and analysed in independent labs by different 
methods. In lab 1 the DNA was hydrolysed using the 0.1 M formic acid method at 70° C and 
the M1dG adduct level was determined to be 21 pmol/µg DNA. Lab 2 prepared separate 
standards and determined the M1dG adduct level to be 18 pmol/µg which was confirmed by 
an LC-MS method in Nashville, USA where it was established as approximately 17 pmol/µg 
by John Plastaras (personal communication). Comparison of the two diluted standards by ISB 
assay gave very similar results for the calibration lines thus validating the methods used for 
preparation of standards and acquirement of calibration lines by independent labs; Lab 1: R
2
 
= 0.95, y = 43862x + 45004, Lab 2: R² = 0.99, y = 38579x + 28721.  
Quantitation of DNA binding by propidium iodide staining 
The effects of residual reagents upon PI staining were investigated and the fluorescent signals 
were similar for an initial wash time of 10 min and overnight (data not shown). CT-DNA 
calibration lines were acquired with a PI incubation time of overnight or 3 h and both gave a 
good correlation between the amount of DNA bound to the membrane and the signal intensity 
(R
2
 = 0.95 and 0.98). However, the shorter incubation time gave the better correlation and a 
higher slope (3304 compared with 1864). The adduct levels were not found to affect the PI 
intensity in either the M1dG-DNA or O
6
CMdG-DNA standards as compared with the CT-
DNA standards (data not shown) 
DNA fragmentation and improvement of DNA binding to NC membranes 
The PI assay revealed major differences in binding to NC membrane between human and CT 
DNA, 1.5-2.5 times more human WBC DNA was binding to the NC membrane as compared 
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to the CT-DNA standards. DNA quantitation for samples and standards was reliable (UV and 
HPLC analysis) so the cause must be due to one of the sample preparation steps. The 
fragmentation of human WBC and CT-DNA following sonication was investigated using 
agarose gel electrophoresis. Differences in fragmentation between CT-DNA and human 
WBC DNA were quite evident; in general CT-DNA fragmented to lower molecular weight 
fragments (100-600 bp) than human genomic DNA (fragments >600 bp). Ultrapure CT-DNA 
(Sigma) gave fragments greater than 600 bp. 
The PI staining showed that a reduction in sonication times and sonication on ice were both 
beneficial to reducing the variability in DNA binding to NC membranes whereas the order, or 
omission, of the sonication and denaturation steps had no effect upon the relative binding of 
different DNA sources. Comparison of the Fisherbrand and Ultrawave sonication baths also 
revealed major differences in DNA binding. Previous papers reported sonication times of 20 
min but 2 min sonication on ice gave a poor calibration line with the Fisherbrand sonicator 
whereas very good calibration lines could be obtained with the Ultrawave sonicator. Hence, 
fragment size is very dependent upon the sonicator used and the sonication time. Sonication 
is known to be a variable method for sample preparation but can be used under carefully 
controlled conditions that need to be verified prior to the ISB assay. Furthermore it is far 
more time and cost effective than enzymatic hydrolysis. 
Further improvement in binding DNA was achieved by keeping the samples on ice after the 
denaturation step until application to the NC membrane (CV = 13%). The PI signals for CT-
DNA and BM DNA were also much closer in intensity, with only 12% and 10% variation 
within each sample set, and a 21% variation overall. Substituting ammonium acetate for 20x 
SSC buffer made no difference to the DNA binding or quality of calibration lines obtained 
(R
2
 = 0.99 for both buffers). 
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The binding of DNA on two different NC membranes was investigated using the PI assay. 
Only 33% of DNA was binding to the 0.45µm membrane compared to the 0.1 µm membrane. 
Baking the membrane at 80° C for 1.5 h in a vacuum oven compared to a normal oven 
resulted in approximately 40% more DNA bound. When the NC membrane was bathed in 
SSC buffer, 44% more DNA was binding to the membrane. However, relative differences in 
binding to the membrane between CT-DNA and human samples, as measured by PI ratios, 
did not alter using either method.  
A critical factor appeared to be the ISB manifold. An increase in the tightness of the manifold 
apparatus by insertion of additional spacers in conjunction with a reduced vacuum during 
aspiration gave more consistent binding across the entire membrane as seen by the variation 
in PI intensity. The CV for the PI signal across the entire plate was improved from 26% to 
15% with a reduction in vacuum from 60 to 0.5 mm Hg and the insertion of three acetate 
layers as additional spacers.  
Reduction of M1dG Levels by chemical modification 
Background adduct levels in DNA can in principal be reduced by chemical modification such 
that the primary antibody does not recognise it. Niedernhofer et al (26) discovered that 
raising the pH causes the M1dG adduct ring to open. This was utilised for subsequent reaction 
with methoxyamine to occur. M1dG levels were reduced in highly modified M1dG-DNA 
following treatment with 5 mM methoxyamine in KP buffer at different pHs. Incubating the 
samples for 16-66 h at -20° C showed a progressive reduction to 42-76% of the original value 
which reduced further with incubation at 37° C (an additional 12% at pH 8.0 and 17% at pH 
9.0). No adverse effect was observed for normal nucleotides whereas treatment with higher 
concentrations of methoxyamine gave a 20-50% decrease in dAp. We also investigated the 
modification with hydroxylamine (data not shown) but this gave less reliable results than the 
methoxyamine experiments. Analysis of methoxyamine treated CT-DNA by IDB assay 
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showed that there was a reduction in background adduct levels for all the treatments (data not 
shown) compared with the untreated CT-DNA. This finding agreed with the HPLC results for 
the highly modified M1dG-DNA. However, use of the methoxyamine-treated CT-DNA to 
prepare standards for the ISB assay gave no benefit in terms of a reduced background signal 
for the ISB calibration line  
Reduction of background adduct levels by whole genome amplification 
Amplification of DNA using the GenomiPhi™ kits, followed by purification, gave good 
yields of high quality DNA. Initial experiments with highly modified O
6
CMdG-DNA showed 
that the adduct levels could be reduced to almost zero or below zero relative to the 
unmodified CT-DNA used for the ISB standards (Table 1). This shows a reduction in adduct 
levels of almost three orders of magnitude i.e. 1 pmol to 2 fmol. Other sources of DNA, 
which should be close to baseline values, all gave adduct levels below the LOD of the ISB 
assay after amplification (Table 1). Amplification of CT-DNA was then performed and the 
amplified DNA used to produce standards for the ISB assay by mixing it with the highly 
modified standard DNA for either M1dG or O
6
CMdG. The calibration lines all had good 
linearity (R
2
 >0.97), however, the O
6
CMdG assay gave a lower background reading as 
indicated by the intercept (2008 compared to 4150 for normal CT-DNA) as was to be 
expected if the adducts had been diluted by the amplification process but the M1dG assay 
actually gave higher background readings. This was verified in triplicate thus the background 
for M1dG is not due solely to adducts in the CT-DNA, but possibly non-specific binding or 
interference from other aspects of the assay. Therefore DNA amplification is not beneficial in 
the case of the M1dG calibration lines but has proven beneficial for O
6
CMdG assay. 
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Table 1 O
6
CMdG adduct levels in amplified DNA measured by ISB (mean ± sd) relative to 
the original CT-DNA standards. The amplification reactions for each sample were prepared 
and performed in triplicate.  
Amplified DNA sample  O
6
CMdG levels (fmol/ µg DNA)  sd 
Unmodified CT DNA -0.18  2.10 
Highly modified O
6
CMdG-DNA 2.33  3.18 
human DNA -0.95  1.09 
Genomiphi kit control DNA -0.57  0.65 
 
M1dG adducts in blood samples from the EPIC study 
162 blood samples were analysed for M1dG adducts and had an average of 1.61 (sd 0.59), 
adducts per 10
7
 normal nucleotides (range 0.36-3.79). These were much lower than 
previously found in the biopsy samples where average levels were 4.45 (sd 2.99) adducts per 
10
7
 (range 0-11.89). The correlation coefficient between the two sets of samples was 0.06, p 
= 0.55. Some of the samples were at, or below, the LOD but as the amplification approach 
had proved unsuccessful for M1dG it was not possible to perform any further analyses. 
O
6
CMdG adducts in blood samples from a processed meat study 
Blood samples were analysed using the optimised ISB procedure but all samples, with one 
exception, had O
6
CMdG levels below the LOD using standards produced from CT-DNA. 
Calibration curves were then produced with the amplified DNA and highly modified CT-
DNA and these samples were reanalysed on a single blot. All samples gave a positive result 
with the amplified DNA calibration line whereas only one sample had a positive result with 
the conventional CT-DNA calibration line. The mean results are shown in Table 2 whilst Fig. 
2 shows that the general trend for each volunteer was a higher adduct level on the processed 
meat diet compared with the vegetarian diet. The data was analysed by Wilcoxon signed 
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ranks test and gave a weak significant difference between processed meat and vegetarian 
diets (Z = -1.782, p = 0.075). The use of amplified DNA for preparation of standards gave an 
increase in sensitivity of 2.6 adducts per 10
7
 nucleotides and the results presented show the 
ability of the technique to differentiate between samples at this level. 
Table 2 O6CMdG adduct levels in human blood DNA from volunteers on a processed meat 
vs vegetarian diet. Adduct analysis was by ISB using standards prepared from amplified 
DNA with correction by PI staining, and statistical analysis by Wilcoxon signed ranks test. 
 Processed meat Vegetarian 
Mean 1.84 1.51 
Range 1.43-2.63 1.29-1.70 
SD 0.43 0.17 
Z = -1.782 p = 0.075 
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Fig.  2 O
6
CMdG adduct levels (mean ± sd, CV = 4-20%) in blood samples from volunteers 
consuming processed meat vs vegetarian diets. Adduct levels were measured by ISB using 
calibration lines produced from amplified DNA. 
DISCUSSION 
When performing any analytical measurements it is essential to have a reliable and accurately 
quantified standard. We have shown that it is possible to quantify a M1dG-DNA standard by 
a number of methods which included an acid hydrolysis step that needed to be optimised for 
the adduct recovery. The calibration lines compared well with those using enzymatic 
cleavage from a different lab. Having obtained and quantified a reliable standard we 
investigated all aspects of the ISB assay. The model of ultrasonic bath did have an effect 
upon DNA binding to the membranes due to the difference in fragmentation that occurred. A 
reduction in sonication time lead to improved binding due to larger DNA fragments being 
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obtained, as would be expected. Fragmentation is usually achieved by enzymatic methods but 
is more time consuming and costly and, therefore sonication is preferable if the 
reproducibility can be assured. Performing the sonication on ice resulted in further 
improvements to DNA binding presumably due to preventing the formation of superheated 
microcavities which may cause localised degradation of the DNA structure to give a number 
of fragments that are too small to be retained upon the NC membrane. The critical factor for a 
successful ISB assay is binding of the DNA to the NC membrane. As expected a smaller pore 
size led to greater binding of DNA and the 0.1 µm membrane is now used for all ISB 
analyses in our group. The PI assay had revealed that DNA binding was often higher on the 
underside of the membrane. One reason could be due to too high a vacuum pulling the DNA 
through the membrane too quickly and preventing efficient binding. A water aspirator is 
typically used for the vacuum and gives around 60 mm Hg. Other groups state that a 
moderate vacuum was used but do not specify the actual vacuum. The use of a vacuum pump 
allowed the vacuum to be reduced to a level that gave improved binding. The best result was 
achieved with a very low vacuum (0-10 mm Hg). Another factor was the tightness of the 
minifold apparatus as the design does not allow the manifold to be tightened sufficiently. The 
insertion of additional spacers helped to prevent bleeding of the DNA from the wells. This is 
a matter that can only be resolved by trial and error as each manifold apparatus will vary 
from the next and will alter with time.  
DNA binding to NC membranes is greater for SS-DNA than DS-DNA due to interactions 
between the negatively charged backbone and the membrane surface. It is known that cations 
such as Mg
2+
 can decrease DNA binding (27) but as we used ultrapure water throughout the 
study this was not an issue. The protocol for the ISB assay includes a heat denaturation step 
followed by cooling on ice. However, the samples need to be removed for subsequent steps 
such as centrifugation and addition of reagents which may result in reannealing of DNA. It is 
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therefore essential to keep the samples as cold as possible until application to the membrane 
to ensure maximum DNA binding. The combination of sonication on ice and keeping 
samples on ice until application to the membrane gave much improved DNA binding, which 
resulted in improved calibration lines and lower CVs for triplicate analyses. It is possible to 
use DS-DNA that has not been fragmented but this results in a reduced chemiluminescence 
signal even when the quantity of DNA matches that of SS-DNA. This is presumably due to 
steric hindrance preventing access to the adduct by the antibody. TEXT DELETED 
The reduction of background levels of M1dG adducts with methoxyamine had looked 
promising initially. However, there were still results where the samples had a lower 
chemiluminescence signal than the bottom standard which should not contain any M1dG 
adducts. An alternative approach using the whole genome amplication technique was 
investigated but still did not give a reduced background signal for M1dG. However, a 
reduction in background levels of adducts using the whole genome amplification approach 
was successful with O
6
CMdG. Furthermore, blood samples that had previously been below 
the limit of detection were reanalysed using the amplified DNA to prepare calibration lines 
and positive results obtained.  Thus, this method may prove useful where adduct levels are 
expected to be low and a high sensitivity is required such as in the case of blood samples. 
However, as the background signal, and hence sensitivity, was not reduced in the case of 
M1dG, this method is not suitable for all adducts. The difference between antibodies to the 
amplified DNA may be due to the monoclonal (M1dG) being more specific than the 
polyclonal (O
6
CMdG), and thus the whole genome amplification approach is more applicable 
to reduction of background signals where polyclonal antibodies are in use. 
The current analysis of M1dG levels in blood samples from participants in the EPIC study 
showed no correlation to earlier results from colorectal samples.  However, an intervention 
study had demonstrated the importance of taking samples at appropriate time points (22). 
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This data indicates that the blood samples may not be useful in the case of M1dG due to the 
timing of samples from the EPIC study but the analysis of urine samples by LC-MS may 
yield more informative data (28). The analysis of blood samples from the processed meat 
study did show a difference in adduct levels compared to the vegetarian diet for the majority 
of subjects with no difference between the sexes. This is the first case of a difference having 
been found between diets for O
6
CMdG adducts and warrants further study to investigate the 
link between red meat or processed meat and colorectal cancer. In particular, the timing of 
samples and correlation with other tissues would need to be verified before application to 
large scale studies such as EPIC. The study would need to be repeated on a larger scale in 
order to have sufficient power to show a significant difference. Clearly, the adduct levels 
were very low and the background signal needs to be reduced using a technique such as 
whole genome amplification for the production of standards.  
CONCLUSIONS 
We found that the combination of many factors was synergistic in effect and led to a level of 
improvement for the ISB assay not seen for a single factor alone. The most important factors 
were the careful control of the fragmentation step if sonication methods were used and the 
manifold vacuum, both of which must be determined experimentally for each set of 
laboratory equipment. The ISB assay has been investigated thoroughly and is now at a point 
where good data can be obtained, even from samples with very low adduct levels such as 
blood. Chemical modification and genome amplification of untreated CT-DNA did not 
improve sensitivity for M1dG but standards produced from whole genome amplification may 
be beneficial in improving assay sensitivity for other adducts such as O
6
CMdG. The samples 
analysed for M1dG have shown that blood DNA may not be a good choice for biomonitoring 
in studies such as EPIC as the timing of sample collection is likely to have been critical. 
However, blood samples may be useful for studying other adducts, such as O
6
CMdG and 
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colorectal cancer risk, once the adducts have been proven to be a good indicator of disease 
risk through large scale studies where timing of samples has been thoroughly investigated. 
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